About 10% of people aged 6 5 years and over suffer from mild to moderate dementia (Hollister, 1985) . Approximately 50-60% of this patient population are presently bclieved to suffer from senile dementia of the Alzheimer typc (SDAT Judd et al., 1986; Rogers er u/., 1986 ). Alzheimer's disease is, thus, the most common cause of behavioural alteration and cognitive reduction in the elderly. A s the percentagc of the total population aged over 65 is steadily increasing, SDAT will become an even more serious health problem. At present, pharmacological agents which stop the progression of SDAT have not been developed. Among the drugs which are most widely used to alleviate the symptoms are the nootropics and metabolically active compounds.
T h e prototype nootropic agent is piracetam (Fig. I ). T h e term was coined to describe the ability of this drug to improve integrative brain mechanisms associated with mental performance (Giurgea, 1982) . T h e term nootropic does not describe the mechanism of action of the compound but rather the general pharmacological profile. T h e main features considered important for thc classification of a nootropic agent are: (i) T h e enhancement of learning and memory.
(ii) T h e facilitation of the flow of information between the cerebral hemispheres.
(iii) T h e enhancement of the general resistance of the brain to physical and chemical injuries.
(iv) T h c lack of usual psychological and general cardiovascular pharmacological activities.
This general pattern of pharmacological activity applies to many potential therapeutic agents, in this paper the term nootropic will refer solely to piracetam and piracctam-like compounds.
Ahbreviations used: SDAT, senile dementia of the Alzhcirner's type; GABA, y-aminobutyric acid; DHET, dihydroergotoxine. (Fig. 1) and vinca alkaloids. e.g. vinpocetine (Fig. I) . Onc of the more interesting of the drugs under dcvclopment is the alkylxanthine, denbufylline (Fig. I) . This paper will briefly review the pharmacological activity of nootropics, metabolically active compounds and denbufylline.
Nootropics d o not have a well-defined mcchanism of action. Piracctam was first prepared as an analogue of y-aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain, in a mechanism-based approach to develop novel hypnotic drugs. However, it is neither a GABAergic agent, nor a hypnotic. Piracetam has subsequently been shown to facilitate learning and retrieval of acquired information in animals (Sara el a/., 1979). T h e compound also improves interhemispheric information transfer through the corpus callosum (Giurgca & Moyersoons, I972), protects the brain against chemical inotoxication (Moyersoons & Guirgea, 1974 ) and produces no sedative or central stimulant activity in animals in doses up to g/kg (Giurgea er d., 1967) . Tentatively, piracetam may have some of its effects by enhancing acetylcholine release (Koppelman & Lishman, 1986) . T h e animal pharmacology of piracetam has attracted considerable interest among pharmaceutical companies and many derivatives have been developed (e.g. pramiracetam, aniracetani, etiracetam. tenilsetam and oxiracetam). T h e major advantage of these compounds is their improved potency in animal models of learning and memory. Piracetam is a drug which has to be administered in large doses, in the clinic doses in exccss of 2 g/day are used routinely.
Despite the promising animal pharmacology, clinical evidence that piracetam will be an effective agent in the treatment of the cognitive symptoms of SDAT is lacking. In an uncontrolled trial, Faleni (1974) reported that 80% of his dementia patients, with mixed aetiologies, showed improvement in mental status after treatment with 400 mg/day for 1 I weeks. In contrast, Stegink (1972) conducted a plaeebocontrolled, double-blind clinical trial of piracetam (2.4 g/day for 8 weeks) in dementia patients; although attention improved, none of the cognitive variables were enhanced. Furthcr well-controlled clinical trials, in selected patients with mild to moderate SDAT, with the more recently dcvelopcd piracetam analogues are required to allow a more complete evaluation of the efficacy of the nootropics.
D H E T is a mixture of dihydrogenated ergot alkaloids. T h c primary evidence for the cerebral metabolic enhancing activity is the compound's ability to improve brain p(,. and electrical activity which has bccn reduced by oligaemic hypovolaemia (Meier-Ruge er d., 1975; 1978) . T h e precise mechanism of action is unclear, but D H E T has been shown to inhibit cerebral cyclic nucleotidc phosphodiestcrase activity and to intluencc central monoamincrgic systems. T h e compound increases neuronal noradrenaline releasc but blocks the postsynaptic cffects of the neurotransmitter at a ,-adrenoceptors. At dopaminergic and serotoninergie systems, the compound has partial agonist activity (Markstcin. 1985) . T h e multiple effccts of D H E T presumably summate to account for the pharmacological activity of the compound. Clinical trials indicate that D H E T produces small but consistent improvements in dementia patients. A comprehensive review of 26 controlled trials with D H E T showed it to be more effective than placebo or positive controls in 24 of them (McDonald, 1979) . It has been suggested that D H E T owes its apparent efficacy to mild antidepressant activity. However, Gaitz et a/. (1977) in a placebo-controlled trial found that D H E T (3 mg/day for 24 weeks) improved cognition independently of the improvement in mood. Further well-controlled clinical trials, performed solely with paticnts with SDAT, are clearly needed. However, metabolic enhancers, such as DHET, d o appear to have at least a small beneficial effect in the treatment of dementia. Further analysis is required to eloscly examine the mcchanism by which this effect is produced.
Vinca alkaloids have also been extensively investigated for their potential in the treatment of dementia. O n c of the most extensively investigated derivatives is vinpocctine. In un animal model of SDAT, scopolamine-induced memory impairment, vinpocetinc protects against the cognitivc disruption (Denoble er d., 1986) . T h e compound also increases cerebral blood flow and glucose utilization in animals (Karpati & Szporny, 1976; Biro er a/., 1976) . Part of the effects of vinpocetine on cerebral blood flow may be due to rheological activity, as the compound improves erythrocyte dcformability (Kuzuya, 1985) . Vinpocctine produces similar effccts on brain electrical activity to DHET. Interestingly. vinpocctine, like DHET, inhibits cyclic nucleotide phosphodiestcrase (Hidaka & Endo, I984), so some of the activity of vinpocetine may be mediatcd via ttic cffects of cyclic nucleotides on neurotransmitter release.
In the clinic, vinpocetine is at lcast as efficacious a s DHET. Specific studies in SDAT have yet to be performed. Howcver, in a double-blind, placebo-controlled trial in patients with mild to moderate dementia, the patients were examined for their underlying actiologics with thc Haschinski ischaemic score. Vinpocctine (5-20 mg thrce times daily for 12 weeks) was effective in all types of patients (Blaha er ul., 1988) . In a further double-blind, placebocontrolled trial (Fcnzyl et d., 19S6) . vinpocetine was significantly superior to placebo in patients with psycho-organic brain syndromc of ill-defined origin. Vinca alkaloids, such as vinpocetine, d o appear, therefore, t o be of some use in the treatmcnt of dementia. Like many o f these agcnts, wellcontrolled trials conductcd specifically in SDAT patients arc still outstanding.
A compound presently undergoing evaluation in the clinic is dcnbufylline. This is an alkylxanthine with a novel activity profilc. T h e compound specifically inhibits a particular cyclic-AMP-specific cyclic nucleotide phosphodiesterasc (Tablc 1) and, thus, potently elevates cortical cyclic A M P levels (Challiss & Nicholson. I98X). In contrast to many xanthines, denbufylline has a relatively weak ability to bind to adcnosinc receptors (Table I ) . T h e compound also improves learning and memory in animals with ischaemiainduced hippocampal lcsions (Nicholson er ( I / . . 1 98X), an effect which may be associated with elevated cyclic AMP levels (Kandel, 1987) . Cell loss in the hippocampus is one of the early problems in Alzheimer's disease, so the use of ischaemia to induce selective hippocampus lesions may be a useful animal model of SDAT. Changes in memory forrnation, personality and emotion are all associated with hippocampus cell loss (Katzman, 1986) . In addition to effects on memory, denbufylline also improves blood cell deformability (Jukna & Nicholson, 1987) and increases the po2 of the oligaemic cerebral cortex (Nicholson & Angersbach, 1986) .
In the clinic, denbufylline (50 mg, three times daily) has been evaluated in two double-blind, placebo-controlled trials, of 3 months duration, in patients with mild to moderate dementia of mixed aetiology (O'Connolly et ul., 1986 (O'Connolly et ul., , 1988 . T h e improvement in the patients' condition was significantly better than with placebo. Prospective studies specifically aimed at SDAT and other forms of dementia are now required to ascertain whether the beneficial effects of denbufylline are restricted to a specific form of dementia.
To summarize, nootropics and metabolically active compounds are of interest as drugs for the treatment of dementia. At present, results with nootropics look less promising than those obtained with metabolically active compounds. The mechanism of action of drugs such as DHET, vinpocetine and denbufylline requires more extensive investigation, this may lead to the clearer understanding of their central effects and to the subsequent development of more specific and effective drugs. In addition, further prospective studies, specifically performed with SDAT patients, are required with all such agents.
